With reference to the drug Durvalumab recently approved by CDSCO for muscle-invasive bladder cancer, consider the following statements: 1. It acts as an immune checkpoint inhibitor by binding to the PD-L1 protein. 2. It is a broad-spectrum antibiotic used to prevent post-surgical infections in cancer patients. Which of the statements given above is/are correct?

Question

Accepted Answer

1 only — Statement 1 is correct as Durvalumab is a monoclonal antibody that inhibits the PD-L1 pathway, allowing the immune system to attack cancer cells. Statement 2 is incorrect as it is an immunotherapy drug for cancer, not an antibiotic for treating infections.

CDSCO Approves Durvalumab for Muscle-Invasive Bladder Cancer

India Participates in BRICS Virtual Summit on Tariffs